Banca Farmafactoring S.p.A.
BFF Bank S.p.A. engages in non-recourse factoring and credit management activities towards public administration bodies and private hospitals in Italy, Croatia, the Czech Republic, France, Greece, Poland, Portugal, Slovakia, and Spain. It offers factoring and lending securities services, payment services, and online deposit account services. The company also undertakes custodian banking for inves… Read more
Banca Farmafactoring S.p.A. (0RON) - Net Assets
Latest net assets as of September 2021: €783.16 Million EUR
Based on the latest financial reports, Banca Farmafactoring S.p.A. (0RON) has net assets worth €783.16 Million EUR as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.06 Billion) and total liabilities (€10.28 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €783.16 Million |
| % of Total Assets | 7.08% |
| Annual Growth Rate | 8.5% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.53 |
Banca Farmafactoring S.p.A. - Net Assets Trend (2016–2020)
This chart illustrates how Banca Farmafactoring S.p.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Banca Farmafactoring S.p.A. (2016–2020)
The table below shows the annual net assets of Banca Farmafactoring S.p.A. from 2016 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | €462.58 Million | +22.62% |
| 2019-12-31 | €377.25 Million | +3.01% |
| 2018-12-31 | €366.24 Million | +0.66% |
| 2017-12-31 | €363.85 Million | +9.02% |
| 2016-12-31 | €333.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Banca Farmafactoring S.p.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67.7% over the analyzed period, indicating profitable operations and earnings retention.
- The company has 0.8% of equity in treasury stock, representing shares repurchased from the open market.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €332.55 Million | 71.89% |
| Common Stock | €131.40 Million | 28.41% |
| Treasury Stock | €3.52 Million | 0.76% |
| Other Components | €2.15 Million | 0.46% |
| Total Equity | €462.58 Million | 100.00% |
Banca Farmafactoring S.p.A. Competitors by Market Cap
The table below lists competitors of Banca Farmafactoring S.p.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
$556.64 Million |
|
Hunan Yussen Energy Technology
SHE:002986
|
$557.04 Million |
|
Metropolis Healthcare Limited
NSE:METROPOLIS
|
$557.10 Million |
|
Create Technology & Science Co Ltd
SHE:000551
|
$557.14 Million |
|
Huayi Brothers Media Corp
SHE:300027
|
$556.54 Million |
|
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
|
$556.52 Million |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
$556.46 Million |
|
SÜSS MicroTec SE
PINK:SESMF
|
$556.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Banca Farmafactoring S.p.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 377,252,270 to 462,578,780, a change of 85,326,510 (22.6%).
- Net income of 91,072,580 contributed positively to equity growth.
- Dividend payments of 168,506,806 reduced retained earnings.
- Share repurchases of 2,702,470 reduced equity.
- Other factors increased equity by 165,463,206.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €91.07 Million | +19.69% |
| Dividends Paid | €168.51 Million | -36.43% |
| Share Repurchases | €2.70 Million | -0.58% |
| Other Changes | €165.46 Million | +35.77% |
| Total Change | €- | 22.62% |
Book Value vs Market Value Analysis
This analysis compares Banca Farmafactoring S.p.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Banca Farmafactoring S.p.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.69%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 13.08x
- Recent ROE (19.69%) is below the historical average (23.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 21.61% | 0.00% | 0.00x | 14.19x | €38.76 Million |
| 2017 | 26.26% | 0.00% | 0.00x | 12.22x | €59.16 Million |
| 2018 | 25.16% | 0.00% | 0.00x | 13.49x | €55.53 Million |
| 2019 | 24.69% | 0.00% | 0.00x | 14.55x | €55.43 Million |
| 2020 | 19.69% | 0.00% | 0.00x | 13.08x | €44.81 Million |
Industry Comparison
This section compares Banca Farmafactoring S.p.A.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Banca Farmafactoring S.p.A. (0RON) | €783.16 Million | 21.61% | 13.13x | $556.56 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |